Premium
Clinical Effects of Long‐Term (36‐Month) Lanthanum Carbonate Administration in Hemodialysis Patients in J apan
Author(s) -
Kishi Yuichiro,
Obara Yoshihiro,
Hara Keiko,
Yamashiro Hiromitsu,
Kurosawa Norio,
Takada Daisuke
Publication year - 2014
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.12197
Subject(s) - medicine , lanthanum carbonate , hyperphosphatemia , dose , hemodialysis , sevelamer , albumin , phosphate binder , dialysis , parathyroid hormone , endocrinology , calcium
In this study, we investigated the clinical effects of long‐term administration of the phosphorus ( P ) binder lanthanum carbonate ( LC ), which was launched in J apan in 2009. The subjects were 58 dialysis patients who began receiving LC , and we evaluated the clinical effects for up to 36 months after treatment initiation. The average serum P concentration remained low during the 36‐month study period, with a significant reduction from 6.25 mg/dL at the start of the study to 4.94 mg/dL after 36 months ( P < 0.001). A significant reduction was also observed in the average serum calcium concentration after 36 months ( P < 0.05), but not in the serum intact parathyroid hormone concentration. Significant reductions were also observed in the average serum total protein, albumin and potassium concentrations ( P < 0.05). The dosages of LC increased by approximately 1.9‐fold after 36 months, in contrast, the dosages of concomitantly used sevelamer hydrochloride and Ca carbonate preparations decreased. These results indicate that LC could be used to treat hyperphosphatemia without causing hypercalcemia, and would be useful for long‐term treatment with hemodialysis patients.